Express Pharma
Home  »  Market  »  IPM clocks Rs 8626 crores in Sept 2015

IPM clocks Rs 8626 crores in Sept 2015


12 therapies have outgrown the IPM growth

The Indian Pharmaceutical Market (IPM) clocked Rs 8626 crores in September 2015. It has grown at 9.9 per cent in the same month. Amongst the top 10, Zydus grew by 12.6 per cent followed by Lupin at 12.4 per cent and Sun at 11.8 per cent. 20 corporates have crossed the growth of IPM amongst the top 50. Amongst the top 50 corporates, Wockhardt had the highest growth of 42.3 per cent followed by Troikaa at 38.2 per cent and AstraZeneca at 37.8 per cent. 18 corporates have shown growths of more than 10 per cent amongst the top 50.

Amongst the 11-20 ranked corporates, Intas had the highest growth of 27.4 per cent followed by Micro at 16.7 per cent and Torrent at 16 per cent. Amongst the 21-30 ranked corporates, Wockhardt had the highest growth at 42.3 per cent followed by MSD at 33.1 per cent and Novartis at 9.7 per cent.


Amongst the 31-40 ranked corporates, AstraZeneca had the highest growth at 37.8 per cent followed by Bharat Serums at 19.1 per cent and Wallace at 19 per cent. Amongst the 41-50 ranked corporates, Troikaa had the highest growth at 38.2 per cent followed by Fourrts at 9.9 per cent and Allergan at 5.5 per cent. Amongst the 51-60 ranked corporates, Boehringer Ingelheim grew at 43.4 per cent followed by Corona at 21.5 per cent and Hegde and Hegde at 19.5 per cent. Amongst the 61-70 ranked corporates, Fresenius Kabi grew at 63.7 per cent followed by RPG by 19.4 per cent followed by TTK at 16.3 per cent. Troikka had become the 50th biggest corporate on MAT Basis and Wallace 40th Biggest Corporate in IPM. Amongst the top 10, Zydus Cadila grew by 12.9 per cent followed by Abbott HC at 12.5 per cent and Lupin at 12.4 per cent.

20 companies have crossed the growth of IPM amongst top 50. Amongst the 21-30 ranked companies, Wockhardt had the highest growth at 42.3 per cent followed by Zuventus 19.9 per cent and Novartis at 9.7 per cent.

Indian companies have grown at 9.6 per cent versus 10.7 per cent for MNCs in September 2015. Amongst the top 50 in MNCs, AstraZeneca grew at 37.8 per cent, MSD grew by 33.1 per cent followed by and Merck at 16 per cent.


The DPCO containing molecules market grew at 2.8 per cent whereas the non-DPCO market grew by 10.9 per cent and non -Sch Para 19 market at 11.5 per cent resulting in an overall growth of 9.9 per cent for September 2015. The NLEM and Non-NLEM category showed unit growth at 1.2 per cent and 1.1 per cent respectively. The non-Sch Para 19 market grew at nine per cent from units perspective.

From therapy perspective, 12 therapies have outgrown the IPM growth. The gynaecological market grew at 13.4 per cent, respiratory market grew at 4.1 per cent, gastrointestinal market grew at 12.8 per cent, pain and analgesics market grew at nine per cent whereas anti-infectives grew at 3.2 per cent. The anti-diabetic market grew at 18.1 per cent and cardiac at 11.8 per cent in chronic business. The derma market grew by 12.9 per cent and the urology market at 12.1 per cent.

From regional perspective, 13 regions have outgrown the IPM growth. The UP East market grew the highest at 20.7 per cent followed by Haryana market at 20.6 per cent and Uttarakhand + UP West market at 18.7 per cent. Four regions had a negative growth in September 2015.

Amoxycillin + Clavulanic acid market grew at 0.6 per cent whereas Glimepiride + Metformin grew at 11.3 per cent at number two. The markets of paracetamol grew at 20.3 per cent, Atorvastatin 2.9 per cent, probiotic microbes at 19.7 per cent, cefixime -3.6 per cent, pantoprazole 7.5 per cent, montelukast + levocetrizine at 5.5 per cent, glimepiride + metformin + pioglitazone at 13.7 per cent, Vitamin-D at 22.3 per cent, hydroquinone + mometasone + tretinoin at 12.3 per cent, voglibose + metformin + glimepiride at 42.9 per cent, rosuvastatin at 22 per cent, protein supplements at -2.6 per cent, azithromycin at minus seven per cent, calcium carbonate + Vit D3 market at 18.1 per cent. Carica papaya became Rs 6 crore market on MAT basis.

Monocef leads the pack with Rs 34 crores followed by Mixtard, Spasmoproxyvon Plus, Augmentin and Corex for September 15. Spasmoproxyvon Plus grew at 127.3 per cent followed by Janumet at 104 per cent, Corex 44 per cent amongst top 10 brands.

Few Brands who have gained ranks include Rotarix (+133), Mifegest Kit (+110), Meronem (+86), Chymoral Forte (+73), Omez (+50), Trajenta (+44), Betnovate C (+41), Vertin (+40), Janumet (+39), Rantac (+32), Panderm Plus, Istamet (+31), Betnesol (+29), levipil (+28), Spasmoproxyvon Plus (+25), Rosuvas (+24), Shelcal (+16), Dolo (+12), Orofer XT (+11), amongst top 100 Brands over September -14.

Caripill moved into Top 500 Brands in September 2015. The 300th biggest brand is Gestofit from Alembic.

A total of 253 brands and 437 SKUs were launched in September 2015. The top new brands in September 2015 were Vilazine, Lupiheme and Vilano. The biggest new launch by an MNC are Amicolon SB, Stugeron Plus and BHRF in September 2015.

About PharmaTrac

PharmaTrac is the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Terminologies used

MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.

For more information, visit

Comments are closed.